FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
-2.68%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.2B
AUM Growth
+$12.2B
(-15%)
Cap. Flow
-$622M
Cap. Flow
% of AUM
-5.09%
Top 10 Holdings %
Top 10 Hldgs %
49.99%
Holding
122
New
16
Increased
44
Reduced
27
Closed
23
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$881M |
| 2 |
IAC Inc
IAC
|
$318M |
| 3 |
Alibaba
BABA
|
$280M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$131M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
$131M |
Top Sells
| 1 |
RHT
Red Hat Inc
RHT
|
$964M |
| 2 |
APC
Anadarko Petroleum
APC
|
$738M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
$394M |
| 4 |
Booking.com
BKNG
|
$130M |
| 5 |
Equifax
EFX
|
$117M |
Sector Composition
| 1 | Healthcare | 42.86% |
| 2 | Technology | 14.15% |
| 3 | Communication Services | 11.41% |
| 4 | Industrials | 6.61% |
| 5 | Consumer Discretionary | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCXI
76
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.7M | 0.1% |
2,013,396
+13,396
| +0.7% | +$90.8K |
|
|
QTNT
77
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $13.2M | 0.1% |
1,700,000
-800,000
| -32% | -$6.22M |
|
78
Acadia Pharmaceuticals
ACAD
$4.3B
| $12.6M | 0.1% |
+350,000
| New | +$12.6M |
|
|
EIGR
79
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $11.5M | 0.09% |
1,125,000
+125,000
| +13% | +$1.28M |
|
80
Savara
SVRA
$591M
| $9.3M | 0.07% |
3,510,787
+35,787
| +1% | +$94.8K |
|
81
Axsome Therapeutics
AXSM
$6.07B
| $8.1M | 0.06% |
+400,000
| New | +$8.1M |
|
82
Exagen
XGN
$212M
| $5.63M | 0.04% |
+363,336
| New | +$5.63M |
|
|
PFNX
83
DELISTED
Pfenex Inc.
PFNX
| $5.06M | 0.04% |
600,000
| – | – |
|
84
Cyclerion Therapeutics
CYCN
$7.72M
| $4.57M | 0.03% |
376,628
-167,457
| -31% | -$2.03M |
|
85
uniQure
QURE
$939M
| $3.97M | 0.03% |
100,922
+922
| +0.9% | +$36.3K |
|
|
GCVRZ
86
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $3.89M | 0.03% |
6,827,805
| – | – |
|
|
DMTK
87
DELISTED
DermTech, Inc. Common Stock
DMTK
| $3.45M | 0.03% |
+615,385
| New | +$3.45M |
|
|
PHAS
88
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $3.37M | 0.03% |
807,928
+50,967
| +7% | +$213K |
|
|
APTX
89
DELISTED
Aptinyx Inc. Common Stock
APTX
| $2.35M | 0.02% |
674,141
+4,141
| +0.6% | +$14.5K |
|
90
Gossamer Bio
GOSS
$587M
| $1.69M | 0.01% |
100,712
+712
| +0.7% | +$12K |
|
91
Coherent
COHR
$13.8B
| $1.68M | 0.01% |
+47,687
| New | +$1.68M |
|
92
Larimar Therapeutics
LRMR
$327M
| $1.34M | 0.01% |
1,808,360
+8,360
| +0.5% | +$6.18K |
|
93
Liberty Global Class C
LBTYK
$4.06B
| – | – |
-3,675,974
| Closed | -$97.5M |
|
94
Milestone Pharmaceuticals
MIST
$153M
| – | – |
-250,000
| Closed | -$6.79M |
|
95
NovoCure
NVCR
$1.33B
| – | – |
-1,200,000
| Closed | -$75.9M |
|
96
Occidental Petroleum
OXY
$45.9B
| – | – |
-20,000
| Closed | -$1.01M |
|
97
Personalis
PSNL
$431M
| – | – |
-184,932
| Closed | -$5.02M |
|
98
SPDR S&P 500 ETF Trust
SPY
$655B
| – | – |
0
| – | – |
|
99
Sarepta Therapeutics
SRPT
$2B
| – | – |
-500,000
| Closed | -$76M |
|
100
T-Mobile US
TMUS
$284B
| – | – |
-425,780
| Closed | -$31.6M |
|